Sphere

Sphere R&D Expenses

The Research & Development Expenses of Sphere (347700.KQ) as of Oct 31, 2026 is 375.11 M KRW. In the previous year, Research & Development Expenses was 481.42 M KRW — a change of -22.08% (lower).

R&D Expenses

375.11 MKRW

YoY

-22.08%

Last updated:

Research & Development Expenses of Sphere is 2025 375.11 M KRW. Research & Development Expenses of Sphere was 2024 481.42 M KRW. It decreases by -22.08% lower compared to the previous year.

The Sphere R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2020
243.33 M KRW
Jan 1, 2021
349.86 M KRW
Jan 1, 2022
470.48 M KRW
Jan 1, 2023
529.77 M KRW
Jan 1, 2024
481.42 M KRW
Jan 1, 2025
375.11 M KRW
The Sphere R&D Expenses history
YEARR&D ExpensesYoY
375.11 MKRW-22.08%
481.42 MKRW-9.13%
529.77 MKRW+12.60%
470.48 MKRW+34.48%
349.86 MKRW+43.78%
243.33 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sphere Stock analysis

What does Sphere do? Sphere Corp, listed under the ticker 347700.KQ and ISIN KR7347700007, is a South Korean health care company headquartered in Seoul. The company went public on March 23, 2021, and currently employs 53 full-time staff. Sphere Corp operates within the health care sector, focusing on digital health technology platforms and solutions. The company's website is https://lifesemantics.kr/, which serves as its primary online presence. Sphere Corp provides a digital health record data platform, enabling personalized health management through technology. The company's offerings include digital health technology platforms and digital health solutions, though specific product names such as LifeRecord, H.AI, OHA, Dr. Call, Redpill care, and Redpill breathtaking are not verified as part of the company's official portfolio. Additionally, Sphere Corp engages in the sale of diagnostic reagents and equipment, though details regarding these products are not elaborated in the provided information. The company's operations are based in Seoul, South Korea, and it is categorized under the health care industry. The information regarding its founding year, key personnel, and specific financial figures is not included in the provided data. Sphere Corp's focus remains on delivering digital health services through its platform, aiming to enhance personalized health care experiences for users. Sphere is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sphere stock

Research & Development Expenses of Sphere is 375.11 M KRW in 2025.

Research & Development Expenses of Sphere changed from 481.42 M KRW to 375.11 M KRW, representing a -22.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses Sphere since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's Sphere historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Sphere

All Key Metrics — Sphere